Advances in Ovarian Cancer Treatment Using a Combination of Statins with Other Drugs

Overview

Journal Front Pharmacol

Date 2023 Jan 23

PMID 36686716

Authors

Lei Xia

Shichao Ding

Xuezhen Wang

Xiaoyu Zhang

Lin Zhu

Hairong Zhang

Huirong Li

Affiliations

Soon will be listed here.

Abstract

New anti-cancer drugs are constantly being developed, especially targeted drugs. Although these drugs have achieved significant clinical efficacy, they do not play a significant role in ovarian cancer. Moreover, the research cycle and costs of such drugs are often huge. The repositioning of conventional drugs has gradually become a concern. Statins, as traditional lipid-lowering drugs, play a role mainly by inhibiting HMGCR. In recent years, epidemiological studies and experiments have confirmed its anti-cancer effect, especially the effect of anti-ovarian cancer. The mutation rate of TP53 in ovarian cancer is as high as 95%, while HMGCR is often highly expressed in TP53 mutant tumors. However, the effect of prospective clinical trials is not ideal. This result seems understandable considering that it seems unrealistic for a lipid-lowering drug to completely inhibit tumor growth. Therefore, statins play more synergistic roles in the treatment of ovarian cancer. Because ovarian cancer is a highly heterogeneous tumor, it may be a good choice to deeply understand the mechanism of statins in the treatment of ovarian cancer and achieve precise treatment by combining it with other drugs.

Citing Articles

Causal role of ischemic heart disease in ovarian cancer subtypes.

Chen J, He H, Gao L Discov Oncol. 2025; 16(1):67.

PMID: 39836328 PMC: 11751212. DOI: 10.1007/s12672-025-01824-9.

Why make it if you can take it: review on extracellular cholesterol uptake and its importance in breast and ovarian cancers.

Lauridsen A, Skorda A, Winther N, Bay M, Kallunki T J Exp Clin Cancer Res. 2024; 43(1):254.

PMID: 39243069 PMC: 11378638. DOI: 10.1186/s13046-024-03172-y.

Drug repositioning and ovarian cancer, a study based on Mendelian randomisation analysis.

Zhu L, Zhang H, Zhang X, Chen R, Xia L Front Oncol. 2024; 14:1376515.

PMID: 38651149 PMC: 11033362. DOI: 10.3389/fonc.2024.1376515.

Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins.

Almeida-Nunes D, Silvestre R, Dinis-Oliveira R, Ricardo S Int J Mol Sci. 2024; 25(1).

PMID: 38203494 PMC: 10779012. DOI: 10.3390/ijms25010323.

Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.

Reiners Jr J, Mathieu P, Gargano M, George I, Shen Y, Callaghan J Cancers (Basel). 2024; 16(1).

PMID: 38201517 PMC: 10778372. DOI: 10.3390/cancers16010089.

References

Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Branes J . Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 2009; 14(5):1180-93. PMC: 3822754. DOI: 10.1111/j.1582-4934.2009.00771.x. View

Ahn K, Sethi G, Aggarwal B . Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol. 2007; 178(4):2507-16. DOI: 10.4049/jimmunol.178.4.2507. View

He S, Ma L, Baek A, Vardanyan A, Vembar V, Chen J . Host CYP27A1 expression is essential for ovarian cancer progression. Endocr Relat Cancer. 2019; 26(7):659-675. PMC: 6824983. DOI: 10.1530/ERC-18-0572. View

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

Yu O, Boudreau D, Buist D, Miglioretti D . Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control. 2008; 20(5):609-16. PMC: 3041638. DOI: 10.1007/s10552-008-9271-1. View

Kobayashi Y, Kashima H, Wu R, Jung J, Kuan J, Gu J . Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. Clin Cancer Res. 2015; 21(20):4652-62. PMC: 4609247. DOI: 10.1158/1078-0432.CCR-14-3368. View

Lee J, Minasian L, Kohn E . New strategies in ovarian cancer treatment. Cancer. 2020; 125 Suppl 24:4623-4629. PMC: 7437367. DOI: 10.1002/cncr.32544. View

Taylor-Harding B, Orsulic S, Karlan B, Li A . Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol. 2010; 119(3):549-56. DOI: 10.1016/j.ygyno.2010.08.017. View

Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P . Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study. BMC Cancer. 2018; 18(1):767. PMC: 6064082. DOI: 10.1186/s12885-018-4676-z. View

10.

Witham J, Valenti M, De-Haven-Brandon A, Vidot S, Eccles S, Kaye S . The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007; 13(23):7191-8. DOI: 10.1158/1078-0432.CCR-07-0362. View

11.

Rao P, Rao U . Statins decrease the expression of c-Myc protein in cancer cell lines. Mol Cell Biochem. 2020; 476(2):743-755. DOI: 10.1007/s11010-020-03940-2. View

12.

McTaggart S . Isoprenylated proteins. Cell Mol Life Sci. 2005; 63(3):255-67. PMC: 11136304. DOI: 10.1007/s00018-005-5298-6. View

13.

Hanley G, Kaur P, Berchuck A, Chase A, Grout B, Deurloo C . Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada. Gynecol Oncol. 2021; 162(2):461-468. PMC: 9398205. DOI: 10.1016/j.ygyno.2021.05.021. View

14.

Schachter M . Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005; 19(1):117-25. DOI: 10.1111/j.1472-8206.2004.00299.x. View

15.

Pastorino J, Shulga N, Hoek J . Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 2001; 277(9):7610-8. DOI: 10.1074/jbc.M109950200. View

16.

Elmore R, Ioffe Y, Scoles D, Karlan B, Li A . Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol. 2010; 111(1):102-5. DOI: 10.1016/j.ygyno.2008.06.007. View

17.

Clendening J, Pandyra A, Boutros P, El Ghamrasni S, Khosravi F, Trentin G . Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A. 2010; 107(34):15051-6. PMC: 2930553. DOI: 10.1073/pnas.0910258107. View

18.

Robinson E, Nandi M, Wilkinson L, Arrowsmith D, Curtis A, Richardson A . Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol Oncol. 2013; 129(2):417-24. DOI: 10.1016/j.ygyno.2013.02.003. View

19.

Lipper C, Stofleth J, Bai F, Sohn Y, Roy S, Mittler R . Redox-dependent gating of VDAC by mitoNEET. Proc Natl Acad Sci U S A. 2019; 116(40):19924-19929. PMC: 6778226. DOI: 10.1073/pnas.1908271116. View

20.

Stine J, Guo H, Sheng X, Han X, Schointuch M, Gilliam T . The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer. Oncotarget. 2015; 7(1):946-60. PMC: 4808044. DOI: 10.18632/oncotarget.5834. View